Compare Wockhardt with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs SUN PHARMA - Comparison Results

WOCKHARDT     Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT SUN PHARMA WOCKHARDT/
SUN PHARMA
 
P/E (TTM) x -45.9 28.4 - View Chart
P/BV x 1.0 2.9 35.4% View Chart
Dividend Yield % 0.0 0.6 0.7%  

Financials

 WOCKHARDT   SUN PHARMA
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
SUN PHARMA
Mar-19
WOCKHARDT/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,012679 149.1%   
Low Rs532375 141.6%   
Sales per share (Unadj.) Rs355.9121.1 293.7%  
Earnings per share (Unadj.) Rs-60.313.4 -450.6%  
Cash flow per share (Unadj.) Rs-46.820.7 -226.1%  
Dividends per share (Unadj.) Rs0.012.75 0.4%  
Dividend yield (eoy) %00.5 0.2%  
Book value per share (Unadj.) Rs257.8172.6 149.4%  
Shares outstanding (eoy) m110.632,399.26 4.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.24.4 49.8%   
Avg P/E ratio x-12.839.4 -32.5%  
P/CF ratio (eoy) x-16.525.5 -64.8%  
Price / Book Value ratio x3.03.1 98.0%  
Dividend payout %020.6 -0.1%   
Avg Mkt Cap Rs m85,3791,264,650 6.8%   
No. of employees `0006.317.5 35.7%   
Total wages/salary Rs m9,37159,671 15.7%   
Avg. sales/employee Rs Th6,295.016,608.1 37.9%   
Avg. wages/employee Rs Th1,498.33,409.6 43.9%   
Avg. net profit/employee Rs Th-1,066.31,833.8 -58.1%   
INCOME DATA
Net Sales Rs m39,369290,659 13.5%  
Other income Rs m1,20210,255 11.7%   
Total revenues Rs m40,571300,914 13.5%   
Gross profit Rs m1863,076 0.0%  
Depreciation Rs m1,49517,533 8.5%   
Interest Rs m2,5555,553 46.0%   
Profit before tax Rs m-2,83050,246 -5.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,582-12,144 29.5%   
Tax Rs m2576,009 4.3%   
Profit after tax Rs m-6,66932,093 -20.8%  
Gross profit margin %021.7 0.2%  
Effective tax rate %-9.112.0 -75.9%   
Net profit margin %-16.911.0 -153.4%  
BALANCE SHEET DATA
Current assets Rs m33,796310,692 10.9%   
Current liabilities Rs m26,917173,396 15.5%   
Net working cap to sales %17.547.2 37.0%  
Current ratio x1.31.8 70.1%  
Inventory Days Days7999 80.1%  
Debtors Days Days89112 80.0%  
Net fixed assets Rs m39,664232,477 17.1%   
Share capital Rs m5532,399 23.1%   
"Free" reserves Rs m27,968411,691 6.8%   
Net worth Rs m28,522414,091 6.9%   
Long term debt Rs m21,73115,226 142.7%   
Total assets Rs m81,620646,938 12.6%  
Interest coverage x-0.110.0 -1.1%   
Debt to equity ratio x0.80 2,072.1%  
Sales to assets ratio x0.50.4 107.4%   
Return on assets %-5.05.8 -86.6%  
Return on equity %-23.47.8 -301.7%  
Return on capital %-7.710.2 -75.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,80766,025 14.9%   
Fx outflow Rs m1,78938,610 4.6%   
Net fx Rs m8,01927,415 29.2%   
CASH FLOW
From Operations Rs m68421,965 3.1%  
From Investments Rs m6,302-6,813 -92.5%  
From Financial Activity Rs m-7,695-27,305 28.2%  
Net Cashflow Rs m-664-8,442 7.9%  

Share Holding

Indian Promoters % 74.5 63.7 117.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 5.1 44.8%  
FIIs % 7.7 23.0 33.5%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 8.3 185.5%  
Shareholders   67,757 133,026 50.9%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT With:   CIPLA  PFIZER  NATCO PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  

Compare WOCKHARDT With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 143 Points Lower; Banking and Finance Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day today, tracking weak global cues as coronavirus cases continue to surge across the world.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

A Warning for Traders: Don't Get Addicted to Hopium(Fast Profits Daily)

Jun 30, 2020

If you are a trader, you must watch out for this dangerous addiction.

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Jul 10, 2020 (Close)

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE WOCKHARDT WITH

MARKET STATS